Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
By: Nasdaq / GlobeNewswire - 24 May 2019 | Back to overview list |
|
WALTHAM, Mass. and CRESTWOOD, Ky., May 24, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on May 17, 2019, the Compensation Committee of the Board of Directors approved the grant of an equity award, as of May 20, 2019, to a new employee as an equity inducement award outside of the Company's 2017 Stock Incentive Plan and material to the employee's acceptance of employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received an option to purchase 48,500 shares of Apellis common stock. The option has an exercise price of $18.43 per share, which is equal to the closing price of Apellis common stock on May 20, 2019, the grant date of the option. One-fourth of the shares underlying the employee option will vest on the one year anniversary of the employee’s date of employment and thereafter 1/48th of the shares underlying each employee option will vest monthly, such that the shares underlying the option granted to the employee will be fully vested on the fourth anniversary of the employee’s date of employment, subject to the employee’s continued employment with Apellis on such vesting date. About Apellis Forward-Looking Statements CONTACT: Media Contact: Liza Sullivan lsullivan@denterlein.com 617.482.0042 (office) 917.981.7494 (mobile) Investor Contact: Alex Kane akane@w2ogroup.com 212.301.7218 (office) 929.400.2691 (mobile) |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |